Most Genes Previously Linked to Cerebral Palsy Lack Strong Statistical Support, Study Finds

Cerebral palsy is the most common cause of physical disability in childhood, affecting up to three children per 1,000 births worldwide. Although it has traditionally been associated with factors such as prematurity, infection and oxygen deprivation around birth, growing evidence suggests that genetic variants may contribute to some cases.

A new study published in The American Journal of Human Genetics examined how strong the evidence actually is for genes previously linked to cerebral palsy. Researchers Peter Robinson and Adam Arterbery from the Jackson Laboratory for Genomic Medicine found that many reported genetic associations have substantially weaker support than might be assumed from the existing literature.

Researchers test genetic assumptions

The researchers reviewed 21 published genetic studies of cerebral palsy and identified 515 genes that had previously been proposed as potentially associated with or causal for the condition.

They then examined evidence across more than 5,500 additional studies, using statistical approaches to evaluate which of those 515 genes had credible support for an association with cerebral palsy.

Only 89 of the 515 genes — fewer than one in five — met the researchers’ threshold for sufficient statistical evidence. The finding suggests that many previously reported candidate genes require stronger validation before they can confidently be considered involved in cerebral palsy.

This does not necessarily mean the remaining genes have no connection to the condition. Rather, the available evidence was insufficient under the researchers’ criteria, highlighting the importance of distinguishing preliminary genetic findings from well-supported associations.

Cerebral palsy as a shared clinical feature

In another part of the study, the researchers performed whole-genome sequencing in 460 children diagnosed with cerebral palsy. Pathogenic or likely pathogenic variants involving 60 genes were identified in approximately 16 percent of participants.

However, only 16 of those 60 genes had strong previous evidence connecting them specifically with cerebral palsy. Finding a pathogenic variant in a child with cerebral palsy does not necessarily establish that the variant directly explains the child’s motor symptoms.

The findings led the researchers to question whether cerebral palsy is always best understood as a single disease entity. Instead, they propose that in some cases it may be more informative to view cerebral palsy as a clinical phenotype that can occur as part of different underlying genetic disorders.

Under this framework, similar motor impairments could arise through different biological pathways and coexist with features of various neurodevelopmental, neurological or metabolic conditions.

A genetic diagnosis could therefore complement the cerebral palsy diagnosis by providing additional information about the underlying disorder and, in some cases, associated health risks.

Implications for care and research

The researchers emphasize that their analysis does not prove that hundreds of previously proposed genes are unrelated to cerebral palsy. It instead shows that evidence supporting many individual gene associations remains limited and requires further validation.

The findings also highlight the need to move beyond simply identifying genetic variants. Researchers increasingly need to determine how a particular genotype relates to a child’s symptoms, clinical course and underlying biological mechanisms.

A more precise understanding of these relationships could eventually improve interpretation of genomic testing and help clinicians recognize children whose cerebral palsy phenotype forms part of a broader genetic disorder.

Identifying an underlying diagnosis may also have implications for clinical follow-up. Some genetic disorders involve additional complications that would not necessarily be predicted from the cerebral palsy diagnosis alone.

The possibility of targeted treatments is more uncertain. While identifying distinct genetic subgroups could eventually support more personalized approaches, the current study does not demonstrate that genetic reclassification will directly lead to new treatments for cerebral palsy.

More broadly, the research illustrates how a familiar clinical diagnosis can encompass substantial biological diversity. As whole-genome sequencing becomes increasingly incorporated into research and clinical practice, scientists may gain a clearer picture of the different genetic and non-genetic pathways that can produce cerebral palsy-like motor symptoms.

Rather than replacing the diagnosis of cerebral palsy, genetic information may ultimately help explain why similar physical manifestations arise in children with very different underlying conditions.